Intensive Care Therapy of Covid-19 Disease in Germany

Multi-center retrospective and prospective observational study of Covid-19 patients with severe or critical illness treated on a German ICU

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID ARDS

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

RWTH Aachen - Department for operative Intensive Care Medicine and intermediate Care, Aachen, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age above 18 years
Covid-19 disease (positive SARS-CoV-2 PCR)

Exclusion criteria

-none

Treatment and study plan

Primary outcomes

Mortality

Time frame: up to 150 days

ICU Mortality of patients

Secondary outcomes

ICU length of stay

Time frame: up to 150 days

Intensive care unit length of stay

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Registry information

Official study title

Intensive Care Therapy of Covid-19 Disease in Germany an Multi-center Observational Study

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Jul 2, 2020
Registry last updated: Jan 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed